{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:02:02Z","timestamp":1791151322155,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.4065\/83.11.1200","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T00:58:04Z","timestamp":1232758684000},"page":"1200-1202","source":"Crossref","is-referenced-by-count":19,"title":["Homocysteine: The Rubik's Cube of Cardiovascular Risk Factors"],"prefix":"10.4065","volume":"83","author":[{"given":"Richard V.","family":"Milani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.4065\/83.11.1200_bib1","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2105\/AJPH.49.10.1349","article-title":"Some factors associated with the development of coronary heart disease: six years' follow-up experience in the Framingham study","volume":"49","author":"Dawber","year":"1959","journal-title":"Am J Public Health Nations Health"},{"key":"10.4065\/83.11.1200_bib2","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jama.290.7.898","article-title":"Prevalence of conventional risk factors in patients with coronary heart disease","volume":"290","author":"Khot","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"10.4065\/83.11.1200_bib3","first-page":"111","article-title":"Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis","volume":"56","author":"McCully","year":"1969","journal-title":"Am J Pathol"},{"issue":"15","key":"10.4065\/83.11.1200_bib4","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1056\/NEJMe068060","article-title":"Homocysteine trials\u2014clear outcomes for complex reasons [editorial]","volume":"354","author":"Loscalzo","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.4065\/83.11.1200_bib5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1172\/JCI10588","article-title":"Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model","volume":"107","author":"Hofmann","year":"2001","journal-title":"J Clin Invest"},{"issue":"9","key":"10.4065\/83.11.1200_bib6","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1161\/hq0901.096582","article-title":"Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in ApoE-deficient mice","volume":"21","author":"Zhou","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9111","key":"10.4065\/83.11.1200_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(05)78090-9","article-title":"Acute hyperhomocysteinaemia and endothelial dysfunction [letter]","volume":"351","author":"Chambers","year":"1998","journal-title":"Lancet"},{"issue":"9","key":"10.4065\/83.11.1200_bib8","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1161\/atvb.21.9.1385","article-title":"Does homocysteine promote atherosclerosis [editorial]?","volume":"21","author":"Lentz","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.4065\/83.11.1200_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1172\/JCI118776","article-title":"The oxidant stress of hyperhomocyst(e)inemia [editorial]","volume":"98","author":"Loscalzo","year":"1996","journal-title":"J Clin Invest"},{"issue":"5","key":"10.4065\/83.11.1200_bib10","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0041-1345(02)03075-0","article-title":"Effect of immunosuppressive regimen on novel markers of atherothrombosis in heart transplantation: homocysteine, c-reactive protein, and mean platelet volume","volume":"34","author":"Mehra","year":"2002","journal-title":"Transplant Proc"},{"issue":"1","key":"10.4065\/83.11.1200_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1076029607308390","article-title":"Homocysteine activates platelets in vitro","volume":"14","author":"Mohan","year":"2008","journal-title":"Clin Appl Thromb Hemost"},{"issue":"22","key":"10.4065\/83.11.1200_bib12","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.jacc.2007.02.044","article-title":"Homocysteine modulates the CD40\/CD40L system","volume":"49","author":"Prontera","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.4065\/83.11.1200_bib13","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1001\/jama.288.16.2015","article-title":"Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis","volume":"288","year":"2002","journal-title":"JAMA"},{"issue":"7374","key":"10.4065\/83.11.1200_bib14","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/bmj.325.7374.1202","article-title":"Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis","volume":"325","author":"Wald","year":"2002","journal-title":"BMJ"},{"issue":"11","key":"10.4065\/83.11.1200_bib15","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.4065\/83.11.1203","article-title":"Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis","volume":"83","author":"Humphrey","year":"2008","journal-title":"Mayo Clinic Proc"},{"issue":"7135","key":"10.4065\/83.11.1200_bib16","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/bmj.316.7135.894","article-title":"Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials","volume":"316","year":"1998","journal-title":"BMJ"},{"issue":"12","key":"10.4065\/83.11.1200_bib17","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0002-9149(98)00710-3","article-title":"Modulatory impact of cardiac rehabilitation on hyperhomocysteinemia in patients with coronary artery disease and \u201cnormal\u201d lipid levels","volume":"82","author":"Ali","year":"1998","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.4065\/83.11.1200_bib18","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1161\/hq1201.100225","article-title":"Vascular outcome in patients with homocystinuria due to cystathionine \u03b2-synthase deficiency treated chronically: a multicenter observational study","volume":"21","author":"Yap","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.4065\/83.11.1200_bib19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jama.291.5.565","article-title":"Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial","volume":"291","author":"Toole","year":"2004","journal-title":"JAMA"},{"key":"10.4065\/83.11.1200_bib20","first-page":"1567","article-title":"Homocysteine lowering with folic acid and B vitamins in vascular disease [published correction appears in N Engl J Med. 2006;355 (7):746]","volume":"354","author":"Lonn","year":"2006","journal-title":"N Engl J Med"},{"issue":"15","key":"10.4065\/83.11.1200_bib21","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMoa055227","article-title":"Homocysteine lowering and cardiovascular events after acute myocardial infarction","volume":"354","author":"Bonaa","year":"2006","journal-title":"N Engl J Med"},{"issue":"8943","key":"10.4065\/83.11.1200_bib22","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"issue":"11","key":"10.4065\/83.11.1200_bib23","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/01.STR.0000185929.38534.f3","article-title":"Vitamin Intervention For Stroke Prevention trial: an efficacy analysis","volume":"36","author":"Spence","year":"2005","journal-title":"Stroke"},{"issue":"5","key":"10.4065\/83.11.1200_bib24","doi-asserted-by":"crossref","first-page":"1563S","DOI":"10.1093\/ajcn\/86.5.1563S","article-title":"Homocysteine, vitamins, and vascular disease prevention","volume":"86","author":"McCully","year":"2007","journal-title":"Am J Clin Nutr"},{"issue":"26","key":"10.4065\/83.11.1200_bib25","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa032845","article-title":"Folate therapy and in-stent restenosis after coronary stenting","volume":"350","author":"Lange","year":"2004","journal-title":"N Engl J Med"},{"issue":"17","key":"10.4065\/83.11.1200_bib26","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"issue":"10","key":"10.4065\/83.11.1200_bib27","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1681\/ASN.V12102181","article-title":"The kidney and homocysteine metabolism","volume":"12","author":"Friedman","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.4065\/83.11.1200_bib28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/ATVBAHA.108.164830","article-title":"The homocysteine paradox [editorial]","volume":"28","author":"Rodionov","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.4065\/83.11.1200_bib29","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1161\/ATVBAHA.108.162743","article-title":"Homocysteine or renal impairment: which is the real cardiovascular risk factor?","volume":"28","author":"Potter","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611606368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611606368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T13:45:40Z","timestamp":1633009540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611606368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0025619611606368"],"URL":"https:\/\/doi.org\/10.4065\/83.11.1200","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}